SAN FRANCISCO — One of the U.S. biotech industry’s preferred partners in China, Jiangsu Hengrui Pharmaceuticals, emphasized its global ambitions and plans for more dealmaking at a presentation at the J.P. Morgan Healthcare Conference Thursday.
“In the last two decades, [Hengrui] has grown from a China-focused generics company to one of the largest innovative medicine companies in the world,” the company’s chief strategy officer, Frank Jiang, said at the conference. “Our vision is to be a global biopharma leader.”
Jiang took the stage amid growing interest in the antibodies and other therapies that are coming out of Chinese biotech companies. The conference was abuzz with chatter about China, and how investors and pharma companies alike have flocked to the country to license promising drug candidates over the last couple of years.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in